WILMINGTON (DE), USA, February 05, 2025 / Biotech Newswire / --

威尔明顿 (DE), 美国, 2025年2月5日 / Biotech Newswire / --

Dermaliq Therapeutics, Inc.

Dermaliq Therapeutics，股份有限公司。

(Dermaliq) today announces that Ralf Paus, M.D., D.Sc., F.R.S.B. has joined the company’s Scientific and Medical Advisory Board.

（Dermaliq）今天宣布，拉尔夫·波斯（RalfPaus），医学博士，博士，F.R.S.B。已加入该公司的科学和医学咨询委员会。

Dermaliq is a private biopharmaceutical company dedicated to developing innovative treatments for hair follicle-related diseases. The hair follicle is a vital mini organ in human skin, responsible for producing pigmented hair shafts, but it remains challenging to effectively target with topical drugs..

Dermaliq是一家私营生物制药公司，致力于开发毛囊相关疾病的创新治疗方法。毛囊是人体皮肤中至关重要的微型器官，负责产生色素沉着的发干，但有效靶向局部药物仍然具有挑战性。。

Prof. Ralf Paus is an authority in clinical dermatology and expert in the biology and pathology of the hair follicle. His expertise will play a pivotal role in guiding the development of DLQ01, a precision drug that specifically targets receptors deep inside the hair follicles to effectively address alopecia and other follicle-related conditions..

拉尔夫·鲍斯教授是临床皮肤病学的权威，也是毛囊生物学和病理学的专家。。。

“We are very pleased to welcome Prof. Ralf Paus to our Scientific and Medical Advisory Board at this exciting time. His unparalleled expertise in alopecia pathophysiology will be instrumental in guiding our clinical strategy as we advance our pipeline”,

“在这个激动人心的时刻，我们非常高兴地欢迎拉尔夫·鲍斯教授来到我们的科学和医学咨询委员会。他在脱发病理生理学方面无与伦比的专业知识将有助于指导我们的临床策略，因为我们正在推进我们的管道”，

said Frank Löscher, PhD Dermaliq CEO.

说弗兰克·洛舍尔， 博士Dermaliq首席执行官.

“Our hyliQ technology enables us to precisely target affected hair follicles and delivering a wide range of molecules to develop novel and highly effective and safe topical treatments.”

“我们的hyliQ技术使我们能够精确定位受影响的毛囊，并提供广泛的分子，以开发新颖，高效和安全的局部治疗方法。”

The company’s lead asset DLQ01 targets prostaglandin receptors to activate hair re-growth in Androgenetic Alopecia (AGA). Its novel,

该公司的主要资产DLQ01针对前列腺素受体，以激活雄激素性脱发（AGA）的头发再生。它的小说，

non-hormonal

非激素类

mode of action halts AGA progression, promotes transition of the follicle from telogen (resting) to anagen (growth), prolongs duration of anagen phase, and re-transforms miniaturized hair follicles back into large mini organs that generate thick, long scalp hair shafts. DLQ01 is designed to be the best-in-class AGA treatment in men and women..

作用模式阻止AGA进展，促进卵泡从休止期（休息）过渡到生长期（生长），延长生长期的持续时间，并将小型毛囊重新转化为产生厚而长的头皮毛干的大型微型器官。DLQ01旨在成为男性和女性最好的AGA治疗方法。。

'I am excited to collaborate with Dermaliq in advancing innovative solutions for alopecia treatment. Namely for the treatment of androgenic alopecia and alopecia areata, we urgently need better and more effective drugs but must overcome the challenge of low follicular bioavailability without damaging the hair follicle or the skin around it.

“我很高兴能与Dermaliq合作，推进脱发治疗的创新解决方案。也就是说，对于雄激素性脱发和斑秃的治疗，我们迫切需要更好和更有效的药物，但必须克服卵泡生物利用度低的挑战，而不损害毛囊或其周围的皮肤。

I am intrigued that Dermaliq’s hyliQ® platform holds out the possibility to significantly increase the bioavailability of topically applied drugs in hair follicles and to thus primarily target these.' .

我很感兴趣的是，Dermaliq的hyliQ®平台有可能显着提高毛囊中局部应用药物的生物利用度，从而主要针对这些药物。”。

stated Ralf Paus.

拉尔夫·帕斯说。

About Ralf Paus, MD, DSc, FRSB

关于Ralf Paus，MD，DSc，FRSB

Prof Paus is Research Professor of Dermatology at the University of Miami Miller School of Medicine, Miami, FL, USA, and an academic dermatologist with > 35 years of experience in dermatology and skin and hair research (>720 PubMed-listed publications, H-index: 119). After studying Medicine in Wuerzburg, Vienna, and Berlin, he became fascinated by the biology and pathology of the hair follicle during post-doctoral studies at Yale University, New Haven, CT.

Paus教授是美国佛罗里达州迈阿密市迈阿密大学米勒医学院皮肤病学研究教授，也是一位学术皮肤科医生，在皮肤病学和皮肤与头发研究方面拥有超过35年的经验（PubMed上市出版物>720篇，H指数：119）。在维也纳维尔茨堡和柏林学习医学后，他在康涅狄格州纽黑文的耶鲁大学进行博士后研究，对毛囊的生物学和病理学着迷。

Following dermatology residency training and a junior faculty position at the Charite University Hospital, Berlin, his last clinical appointment was as Professor and Vice Chair, Dept. of Dermatology, University Hospital Hamburg-Eppendorf (1999-2004). Since then, Prof Paus has focused on translational hair research and skin neuroendocrinology, first as Head of Experimental Dermatology, University of Luebeck, then as Director of Research, Centre for Dermatology Research, University of Manchester, where he is now the Emeritus Professor of Cutaneous Medicine.

在柏林Charite大学医院接受皮肤科住院医师培训和初级教师职位后，他最后一次临床任命是汉堡埃彭多夫大学医院皮肤科教授兼副主席（1999-2004）。从那时起，波斯教授一直专注于转化毛发研究和皮肤神经内分泌学，先是卢贝克大学实验皮肤科主任，然后是曼彻斯特大学皮肤病研究中心研究主任，现在是皮肤医学名誉教授。

He served as Editor of .

他担任过的编辑。

Experimental Dermatology

实验皮肤病学

(2007-2021) and is a serial entrepreneur, most recently as Founder & CEO of CUTANEON – Skin & Hair Innovations, Hamburg & Berlin, Germany.

（2007-2021年），是一位连续创业者，最近担任德国汉堡和柏林皮肤与头发创新公司CUTANEON的创始人兼首席执行官。

About

关于

Dermaliq Therapeutics Inc.

Dermaliq Therapeutics股份有限公司。

Dermaliq Therapeutics Inc. is a clinical-stage dermatology company developing innovative treatments for skin follicle-related diseases. With a strong pipeline of drug candidates, we are dedicated to advancing medical dermatology through cutting-edge research and technology.

Dermaliq Therapeutics Inc.是一家临床阶段皮肤病公司，开发针对皮肤毛囊相关疾病的创新治疗方法。凭借强大的候选药物渠道，我们致力于通过尖端研究和技术推进医学皮肤病学。

Our mission is to pioneer novel topical therapies that precisely deliver active compounds into follicular and glandular tissues. Using our proprietary hyliQ

我们的使命是开创新的局部治疗方法，将活性化合物精确地传递到卵泡和腺体组织中。使用我们专有的hyliQ

®

®

technology, we significantly enhance drug bioavailability, enabling the development of highly effective and safe treatments for conditions like alopecia.

技术上，我们显着提高了药物的生物利用度，从而能够开发出针对脱发等疾病的高效和安全的治疗方法。

About DLQ01

关于DLQ01

Dermaliq’s lead asset DLQ01 targets the prostaglandin receptor to stimulate hair re-growth. The recent Phase 2a trial demonstrated efficacy, safety, and clear advantages over current standard of care. Favorable FDA-feedback is paving a clear regulatory development path.

Dermaliq的主要资产DLQ01靶向前列腺素受体以刺激头发再生。最近的2a期临床试验显示，与目前的护理标准相比，疗效，安全性和明显优势。FDA的良好反馈为监管发展铺平了道路。

Dermaliq is actively seeking strategic partners and investors for its current Series B financing round. This funding will support the continued development of our innovative dermatology pipeline including the phase 2b development of DLQ01 in androgenic alopecia, as we strive to bring breakthrough treatments for Alopecia and other dermatological conditions to market..

Dermaliq正在积极寻找战略合作伙伴和投资者，以进行当前的B轮融资。这笔资金将支持我们创新的皮肤病学渠道的持续发展，包括DLQ01在雄激素性脱发中的2b期开发，因为我们努力将脱发和其他皮肤病的突破性治疗推向市场。。

Contact

联系人

Dermaliq Therapeutics Inc.

Dermaliq Therapeutics Inc. 公司

Frank Loescher

弗兰克 Loescher

Chief Executive Officer

This email address is being protected from spambots. You need JavaScript enabled to view it.

此电子邮件地址受到垃圾邮件的保护。。

Keywords: Humans; Diffuse alopecia; Alopecia Areata; Hair Follicle; Receptors, Prostaglandin; Biological Availability; Hair; Hair Diseases; Drug Development; North America; Dermaliq Therapeutics; Scientific and Medical Advisory Board; Ralf Paus; Alopecia; Hair follicle; DLQ01; Prostaglandin receptors; Androgenetic Alopecia (AGA); hyliQ technology; Topical treatments; Hair re-growth; Phase 2a trial; Series B financing; Follicular and glandular tissues; Skin neuroendocrinology; Experimental Dermatology.

关键词：人类；弥漫性脱发；斑秃；毛囊；受体，前列腺素；；头发；头发疾病；药物开发；北美；Dermaliq Therapeutics；科学和医学咨询委员会；拉尔夫·波斯；脱发；毛囊；DLQ01；前列腺素受体；雄激素性脱发（AGA）；hyliQ技术；局部治疗；头发重新生长；2a期试验；B系列融资；卵泡和腺体组织；皮肤神经内分泌学；。

Source: Biotech Newswire

资料来源：Biotech Newswire